Copyright
©The Author(s) 2018.
World J Gastroenterol. Oct 21, 2018; 24(39): 4428-4435
Published online Oct 21, 2018. doi: 10.3748/wjg.v24.i39.4428
Published online Oct 21, 2018. doi: 10.3748/wjg.v24.i39.4428
Table 1 Nanotechnology based drug delivery systems for colorectal cancer targeting
System | Chemotherapeutic agent | Significance | Ref. |
Nanoparticles | Resveratrol (RSV) | Sustained release of RSV (over 72 h), and drug solubility enhancement | [17] |
Micellar delivery system | Docetaxel | Enhanced the efficacy of hydrophobic chemotherapy and reduced systemic toxicity | [18] |
Self-nanoemulsifying drug delivery systems (SNEDDS) | Sunitinib malate | Enhancement of in vitro dissolution rate and anticancer potential of drugs possessing low water solubility such as sunitinib malate | [19] |
Small molecule-based theranostic system, Gal-Dox | Doxorubicin | Drug localization and site of action can be monitored | [20] |
Polymeric micelles | Tanshinone IIA (TAN) | Improved efficacy of anticancer drugs and promoted the growth of beneficial commensal flora in the gut | [21] |
Pressure-sensitive nanogels | 5-Fluorouracil (5-FU) | Higher 5-FU intracellular accumulation and a significant cell death extension by apoptosis | [22] |
Microspheres | Atorvastatin and celecoxib | Synergistic effect on colon cancer prevention and inhibition | [23] |
Microbeads | Doxorubicin | Exhibited reduction-responsive character, release the DOX in reducing environments due to cleavage of the disulfide linkers | [24] |
Carboxymethyl dextran (CMD) chitosan nanoparticles | Small interfering RNA | Significant changes of Epithelial mesenchymal transition genes and apoptosis | [25] |
Liposomes | Apatinib | cRGD-modified liposomes displayed greater apoptosis | [26] |
Table 2 Overview of clinical trials of colorectal cancer
Therapy | Agent | Clinical status | Ref. |
Five peptides combination with oxaliplatin-based chemotherapy | Oxaliplatin | Phase II | [34] |
Panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) vs FOLFOX4 alone | Fluorouracil, Oxaliplatin | Phase III trial | [35] |
Checkpoint inhibitors | Nivolumab and pembrolizumab | Phase 2 study | [36] |
Combination vaccine treatment of five therapeutic epitope-peptides | Fluorouracil, irinotecan or oxaliplatin | Phase I | [37] |
Autologous dendritic cell based adoptive immunotherapy | - | Phase I-II | [38] |
Autologous antigen-activated dendritic cells in the treatment of CRC | - | Phase I-II | [39] |
Adjuvant chemotherapy (FOLFOX) | 5-fluorouracil (FU)/leucovorin (LV) | Phase III | [40] |
- Citation: Tiwari A, Saraf S, Verma A, Panda PK, Jain SK. Novel targeting approaches and signaling pathways of colorectal cancer: An insight. World J Gastroenterol 2018; 24(39): 4428-4435
- URL: https://www.wjgnet.com/1007-9327/full/v24/i39/4428.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i39.4428